Bromelain is a proteolytic enzyme that is used as an anti-inflammatory drug. Administration of Bromelain through the oral route is a challenge in children, who have difficulty swallowing tablets. In the present study, six batches of Bromelain Mouth Dissolving tablets (MDT) dosage form at the dose of 100 mg were formulated and evaluated. Results showed that the thickness, weight variation, friability, hardness, and content uniformity of all six formulations were within acceptable limits. But in the in-vitro dissolution study formulation 3 demonstrated better cumulative drug release than other formulations. Hence the study concludes that Bromelain month dissolving tablets formulated using crospovidone (Formulation 3) showed better characteristics of mouth dissolving tablets.